

NO6000

15

**Claims.**

- 54  
54
1. Use of a composition, which comprises at least one lipid wherein the lipid provides greater than 35% total energy of the composition for use in the manufacture of a medicament, functional food or nutritive product for the treatment or prevention of sepsis or inflammatory shock.
- 10 2. A method of treatment or prevention of sepsis or inflammatory shock which comprises administering an effective amount of a composition, which comprises at least one lipid wherein the lipid provides greater than 35% total energy of the composition.
- 15 3. A method of producing a composition which comprises at least one lipid wherein the lipid provides greater than 35% total energy of the composition, having the steps of blending the constituents, liquefying the blended mixture and homogenising.
- 20 4. A composition for use as a medicament, functional food or nutritive product, which comprises at least one lipid wherein the lipid provides greater than 35% total energy of the composition, which further comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.
- 25 5. A composition according to claim 4, which comprises a n-6/n-3 fatty acid ratio of about 2/1 to 7/1.
- 30 6. A composition according to claim 4 or 5, which comprises at least one n-3 fatty acid selected from  $\alpha$ -linolenic acid, EPA, DPA or DHA.
- 35 7. A composition according to any of claim 4 to 6, which comprises at least one n-6 fatty acid selected from linoleic acid (18:2,n-6),  $\gamma$ -linolenic acid (18:3, n-6), dihomo- $\gamma$ -linoleinic acid (18:4, n-6) or arachidonic acid (20:4, n-6).
8. A composition according to any of claim 4 to 7 for enteral administration which comprises an acceptable carrier, diluent or adjuvant.
- add AS